uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Association of warfarin dose with genes involved in its action and metabolism
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Clinical pharmacogenomics and osteoporosis.ORCID iD: 0000-0002-6368-2622
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Clinical Pharmacology.
Show others and affiliations
Responsible organisation
2007 (English)In: Human Genetics, ISSN 0340-6717, E-ISSN 1432-1203, Vol. 121, no 1, 23-34 p.Article in journal (Refereed) Published
Abstract [en]

We report an extensive study of variability in genes encoding proteins that are believed to be involved in the action and biotransformation of warfarin. Warfarin is a commonly prescribed anticoagulant that is difficult to use because of the wide interindividual variation in dose requirements, the narrow therapeutic range and the risk of serious bleeding. We genotyped 201 patients for polymorphisms in 29 genes in the warfarin interactive pathways and tested them for association with dose requirement. In our study, polymorphisms in or flanking the genes VKORC1, CYP2C9, CYP2C18, CYP2C19, PROC, APOE, EPHX1, CALU, GGCX and ORM1-ORM2 and haplotypes of VKORC1, CYP2C9, CYP2C8, CYP2C19, PROC, F7, GGCX, PROZ, F9, NR1I2 and ORM1-ORM2 were associated with dose (P < 0.05). VKORC1, CYP2C9, CYP2C18 and CYP2C19 were significant after experiment-wise correction for multiple testing (P < 0.000175), however, the association of CYP2C18 and CYP2C19 was fully explained by linkage disequilibrium with CYP2C9*2 and/or *3. PROC and APOE were both significantly associated with dose after correction within each gene. A multiple regression model with VKORC1, CYP2C9, PROC and the non-genetic predictors age, bodyweight, drug interactions and indication for treatment jointly accounted for 62% of variance in warfarin dose. Weaker associations observed for other genes could explain up to approximately 10% additional dose variance, but require testing and validation in an independent and larger data set. Translation of this knowledge into clinical guidelines for warfarin prescription will be likely to have a major impact on the safety and efficacy of warfarin.

Place, publisher, year, edition, pages
2007. Vol. 121, no 1, 23-34 p.
Keyword [en]
warfarin, pharmacogenetics
National Category
Medical and Health Sciences
URN: urn:nbn:se:uu:diva-23778DOI: 10.1007/s00439-006-0260-8ISI: 000244187100002PubMedID: 17048007OAI: oai:DiVA.org:uu-23778DiVA: diva2:51552
Available from: 2008-01-18 Created: 2009-03-24 Last updated: 2016-02-19

Open Access in DiVA

No full text

Other links

Publisher's full textPubMedhttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=17048007&dopt=Citation

Search in DiVA

By author/editor
Wadelius, MiaEriksson, NiclasWadelius, Claes
By organisation
Clinical pharmacogenomics and osteoporosisClinical PharmacologyDepartment of Genetics and Pathology
In the same journal
Human Genetics
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 276 hits
ReferencesLink to record
Permanent link

Direct link